Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730.

Abstract

OBJECTIVE:

To determine the efficacy and safety of a platelet activating factor (PAF) antagonist, BN 50730, in patients with rheumatoid arthritis.

METHODS:

Ten patients with an active disease were treated for 4 weeks with a PAF receptor antagonist, BN 50730, given orally (40 mg twice daily). The treatment period was followed by a 4 weeks followup period.

RESULTS:

Clinical indicators of disease activity significantly improved during the treatment period, with a progressive return to baseline values during the followup period. No significant change in laboratory variables was observed. The tolerance of the treatment was excellent, and no clinical or laboratory evidence of side effects was recorded.

CONCLUSION:

These results need to be confirmed in a controlled study, but suggest an antiinflammatory effect. PAF antagonists could represent a new class of therapeutic agents in inflammatory arthropathies.

• Authors: P Hilliquin, P Guinot, V Chermat-Izard, X Puechal, C J Menkes
• Journal: The Journal of rheumatology (J Rheumatol) Vol. 22 Issue 9 Pg. 1651-4 (Sep 1995) ISSN: 0315-162X [Print] Canada
• PMID: 8523338 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Azepines
• Platelet Aggregation Inhibitors
• Thienopyridines
• Triazoles
• BN 50730

Topics

• Adult
• Aged
• Arthritis, Rheumatoid (complications, drug therapy)
• Azepines (therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Platelet Aggregation Inhibitors (therapeutic use)
• Severity of Illness Index
• Thienopyridines
• Treatment Outcome
• Triazoles (therapeutic use)